---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124581"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:05:19.858613+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026

## Summary
- Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.
- Net loss of $21.2M ($0.35/share) vs $23.0M ($0.56/share) in Q3 2023.
- R&D expenses rose to $17.7M from $14.7M due to increased clinical trial costs for PYX-201 and PYX-106.
- Preliminary Phase 1 data for lead ADC PYX-201 to be presented at investor event on Nov 20, 2024; 80 patients dosed.
- Phase 1 data for PYX-106 (Siglec-15 antibody) expected by year-end 2024; 45 patients dosed.

## SEC filing metadata
- accession: 0000950170-24-124581
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024124581/0000950170-24-124581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024124581/pyxs-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124581
- JSON: https://secwatch.observer/filing/0000950170-24-124581.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.